Osimertinib with or without savolitinib as first‑line treatment for MET‑aberrant, EGFR‑mutant NSCLC: randomized phase 2 trial (FLOWERS)
The combination of osimertinib with savolitinib improves progression‑free survival and tumor response rates compared with osimertinib monotherapy in patients with MET‑aberrant, EGFR‑mutant non‑small cell lung cancer.
A groundbreaking phase 2 clinical trial has unveiled promising advancements in the treatment landscape for non‑small cell lung cancer (NSCLC), specifically targeting patients harboring epidermal growth factor receptor (EGFR) mutations alongside MET gene aberrations. The FLOWERS trial meticulously explored the efficacy of osimertinib – a third‑generation EGFR tyrosine kinase inhibitor (TKI) – administered alone versus its combination with savolitinib, a potent MET inhibitor, as a frontline therapeutic strategy.
The combination therapy demonstrated a profound enhancement in clinical outcomes, showcasing transformative potential for a subset of NSCLC patients facing resistance.
Bizonyítékszint: Állatkísérletes. Állatmodellben vizsgálták.
Kapcsolódó jelek
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT